SCHEDULE: Vanguard Group Reports 0% Stake in Axsome Therapeutics

The Vanguard Group has reported a 0% beneficial ownership in Axsome Therapeutics Inc. following an internal corporate realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 4 to Schedule 13G for Axsome Therapeutics Inc.
• The filing indicates that The Vanguard Group now holds 0.00 shares, representing 0% of the class of Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions will report beneficial ownership separately, and The Vanguard Group, Inc. no longer has beneficial ownership over these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Axsome Therapeutics, as it primarily reflects an internal organizational change at The Vanguard Group rather than a direct investment decision based on Axsome's fundamentals. The impact on Axsome's stock price is likely minimal unless misconstrued by the market.

Positives

• No direct positives for Axsome Therapeutics are identified in this filing, as it primarily reflects an internal organizational change at The Vanguard Group.

Negatives

• The Vanguard Group, a major institutional investor, no longer directly holds beneficial ownership in Axsome Therapeutics, which could be perceived negatively by some investors despite being due to internal restructuring.

Risks

• The filing itself does not detail specific risks for Axsome Therapeutics. The primary risk is the potential market perception of a large institutional investor reducing its reported stake to zero, even if due to internal restructuring rather than a fundamental change in investment thesis.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Axsome Therapeutics or The Vanguard Group's future investment strategies beyond the immediate reporting change.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that internal realignments leading to changes in beneficial ownership reporting are not uncommon among large asset managers like The Vanguard Group. This particular filing reflects a shift in how Vanguard's various entities report their holdings, rather than a strategic divestment based on Axsome Therapeutics' performance. Such disaggregated reporting can provide more granular insight into specific fund or division holdings, though the aggregate institutional ownership might remain similar across Vanguard's broader family of funds.

Stakeholder Impact

• Shareholders: Existing shareholders of Axsome Therapeutics might perceive the reduction to 0% beneficial ownership by The Vanguard Group as a negative signal, potentially leading to short-term price volatility, even if the underlying reason is an internal restructuring.
• The Vanguard Group Investors: Investors in Vanguard funds may see their holdings in Axsome Therapeutics now reported under different Vanguard entities, reflecting the internal realignment.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately in reliance on SEC Release No. 34-39538.

Key Dates

Recommendation

While The Vanguard Group's direct beneficial ownership in Axsome Therapeutics has dropped to 0% due to an internal realignment, this does not necessarily reflect a negative outlook on Axsome's fundamentals. The securities are now reported by other Vanguard entities. Investors should hold and monitor Axsome's performance and other institutional ownership changes, as this filing alone does not provide a basis for a buy or sell decision.

Keywords

Axsome Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Corporate Realignment